High Blood Pressure & Cardiovascular Prevention

, Volume 16, Issue 4, pp 183–193 | Cite as

Clinical Experience with Pheochromocytoma in a Single Centre Over 16 Years

  • Dario Cotesta
  • Luigi Petramala
  • Valentina Serra
  • Mario Pergolini
  • Eleonora Crescenzi
  • Laura Zinnamosca
  • Giorgio De Toma
  • Antonio Ciardi
  • Iacopo Carbone
  • Rita Massa
  • Sebastiano Filetti
  • Claudio Letizia
Original Research Article


Background: Pheochromocytoma and paraganglioma are rare tumours of neuroectodermal origin. Pheochromocytoma occurs in 0.1–2% of people with hypertension, while the incidence rises to 4–5% in patients with incidental adrenal mass.

Aim: To analyse the presentation, diagnosis and localization, pathology, molecular genetic aspects, surgical management and long-term outcome of a large series of patients with pheochromocytoma referred to a single centre.

Methods: From 1992 to 2008, we observed 91 patients with pheochromocytoma, 70 (77%) with the sporadic form and 21 (23%) with the hereditary form. In the group with the hereditary form, the mean age at diagnosis was significantly lower than the mean age of the group with the sporadic form (38 vs 48 years; p < 0.001).

Results: Eighty (88%) patients with pheochromocytoma were symptomatic and the classical triad of palpitations, headache and diaphoresis was present in 30% of patients. In 12% of patients, the pheochromocytoma was discovered during radiological images (adrenal incidentaloma). The unilateral adrenal localization was observed in 78% of patients, bilateral in 15% and extra-adrenal in 7% of patients. All pheochromocytoma patients underwent surgical procedure and the laparotomic approach was used in 49 (53%) patients, while the laparoscopic approach was performed in 42 (47%) patients. Pheochromocytoma was benign in 86 patients (93%) [mean size was 4.3 cm] and the malignant form was found in five patients (7%) [mean size was 10 cm].

Conclusions: These data from a large cohort of patients are consistent with those reported in the literature and show that pheochromocytoma is an in important challenge for clinicians.


pheochromocytoma paraganglioma RET VHL NF1 SDH 



This work is not under active consideration for publication, has not been accepted for publication, nor has it been published, in full or in part. We confirm that the study has been approved by the ethics committee of our institution (Department of Clinical Sciences “Sapienza” University, Rome, Italy).

The authors have no conflicts of interest and each of them have read and approved the article. No sources of funding were used to assist in the preparation of this article.


  1. 1.
    Bausch B, Boedeker CC, Berlis A, et al. Genetic and clinical investigation of pheochromocytoma: a 22-year experience, from Freiburg, Germany to international effort. Ann N Y Acad Sci 2006 Aug; 1073: 122–37PubMedCrossRefGoogle Scholar
  2. 2.
    Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000 Feb; 85(2): 637–44PubMedCrossRefGoogle Scholar
  3. 3.
    Lenders JW, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet 2005 Aug 20-26; 366(9486): 665–75PubMedCrossRefGoogle Scholar
  4. 4.
    Reisch N, Peczkowska M, Januszewicz A, et al. Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens 2006 Dec; 24(12): 2331–9PubMedCrossRefGoogle Scholar
  5. 5.
    Manger WM. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann N Y Acad Sci 2006 Aug; 1073: 1–20PubMedCrossRefGoogle Scholar
  6. 6.
    Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004 Sep; 11(3): 423–36PubMedCrossRefGoogle Scholar
  7. 7.
    Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993 Nov 18; 329(21): 1531–8. Erratum in: N Engl J Med 1994 Dec 1; 331 (22): 1535PubMedCrossRefGoogle Scholar
  8. 8.
    Neumann HP, Pawlu C, Peczkowska M, et al., European-American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004 Aug 25; 292(8): 943–51. Erratum in: JAMA 2004 Oct 13; 292 (14): 1686PubMedCrossRefGoogle Scholar
  9. 9.
    National Institute of Health. Neurofibromatosis: conference statement. National Institute of Health Consensus Development Conference. Arch Neurol 1988; 45: 575–8Google Scholar
  10. 10.
    Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997 Jul 2; 278(1): 51–7PubMedCrossRefGoogle Scholar
  11. 11.
    Bausch B, Borozdin W, Mautner VF, et al., European-American Phaeochromocytoma Registry Study Group. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 2007 Jul; 92(7): 2784–92PubMedCrossRefGoogle Scholar
  12. 12.
    Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [published erratum appears in J Hypertens 2007 Aug; 25 (8): 1749]. J Hypertens 2007 Jun; 25(6): 1105–87PubMedCrossRefGoogle Scholar
  13. 13.
    Lloyd RV, Tischer AS, Kimura N, et al. Adrenal tumors: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, et al., editors. World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. Lyon: IARC Press, 2004: 136–8Google Scholar
  14. 14.
    Neumann HP, Bausch B, McWhinney SR, et al., Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002 May 9; 346(19): 1459–66PubMedCrossRefGoogle Scholar
  15. 15.
    Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003 Aug; 24(4): 539–53PubMedCrossRefGoogle Scholar
  16. 16.
    Dluhy RG. Pheochromocytoma: death of an axiom. N Engl JMed 2002 May 9; 346(19): 1486–8CrossRefGoogle Scholar
  17. 17.
    Maher ER, Eng C. The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 2002 Oct 1; 11(20): 2347–54PubMedCrossRefGoogle Scholar
  18. 18.
    Yeo H, Roman S. Pheochromocytoma and functional paraganglioma. Curr Opin Oncol 2005 Jan; 17(1): 13–8PubMedCrossRefGoogle Scholar
  19. 19.
    Toledo SP, dos Santos MA, Toledo Rde A, et al. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics (Sao Paulo) 2006 Feb; 61(1): 59–70CrossRefGoogle Scholar
  20. 20.
    Gimm O, Koch CA, Januszewicz A, et al. The genetic basis of pheochromocytoma. Front Horm Res 2004; 31: 45–60PubMedGoogle Scholar
  21. 21.
    Peczkowska M, Januszewicz A. Multiple endocrine neoplasia type 2. Fam Cancer 2005; 4(1): 25–36PubMedCrossRefGoogle Scholar
  22. 22.
    Modigliani E, Vasen HM, Raue K, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med 1995 Oct; 238(4): 363–7PubMedCrossRefGoogle Scholar
  23. 23.
    Teh BT. Multiple endocrine neoplasia. J Intern Med 2003 Jun; 253(6): 588–9PubMedCrossRefGoogle Scholar
  24. 24.
    Eng C, Crossey PA, Mulligan LM, et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 1995 Dec; 32(12): 934–7PubMedCrossRefGoogle Scholar
  25. 25.
    Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990 Nov; 77(283): 1151–63PubMedCrossRefGoogle Scholar
  26. 26.
    Friedrich CA. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet 2001 Apr; 10(7): 763–7PubMedCrossRefGoogle Scholar
  27. 27.
    Opocher G, Conton P, Schiavi F, et al. Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer 2005; 4(1): 13–6PubMedCrossRefGoogle Scholar
  28. 28.
    Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990 Jul 13; 62(1): 193–201PubMedCrossRefGoogle Scholar
  29. 29.
    Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992 Apr 23; 356(6371): 713–5PubMedCrossRefGoogle Scholar
  30. 30.
    Walther MM, Herring J, Enquist E, et al. von Recklinghausen’s disease and pheochromocytomas. J Urol 1999 Nov; 162(5): 1582–6PubMedCrossRefGoogle Scholar
  31. 31.
    Cotesta D, Erlic Z, Petramala L, et al. Coincidence of neurofibromatosis type 1 and multiple endocrine neoplasia type 2. Endocrinologist 2008; 6: 277–81CrossRefGoogle Scholar
  32. 32.
    Eng C, Kiuru M, Fernandez MJ, et al. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 2003 Mar; 3(3): 193–202PubMedCrossRefGoogle Scholar
  33. 33.
    Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 2002 Oct; 87(10): 4771–4PubMedCrossRefGoogle Scholar
  34. 34.
    Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001 Jul; 69(1): 49–54PubMedCrossRefGoogle Scholar
  35. 35.
    Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005 Dec 1; 23(34): 8812–8PubMedCrossRefGoogle Scholar
  36. 36.
    Burnichon N, Rohmer V, Amar L, et al. PGL.NET network. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009 Aug; 94(8): 2817–27PubMedCrossRefGoogle Scholar
  37. 37.
    Whiting MJ, Doogue MP. Advances in biochemical screening for phaeochromocytoma using biogenic amines. Clin Biochem Rev 2009 Feb; 30(1): 3–17PubMedGoogle Scholar
  38. 38.
    Procopiou M, Finney H, Akker SA, et al. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. Eur J Endocrinol 2009 Jul; 161(1): 131–40PubMedCrossRefGoogle Scholar
  39. 39.
    Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. International Symposium on Pheochromocytoma; 2005 Oct. Nat Clin Pract Endocrinol Metab 2007 Feb; 3(2): 92–102PubMedCrossRefGoogle Scholar
  40. 40.
    Jacques AE, Sahdev A, Sandrasagara M, et al. Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol 2008 Dec; 18(12): 2885–92PubMedCrossRefGoogle Scholar
  41. 41.
    Eisenhofer G. Pheochromocytoma: recent advances and speed bumps in the road to further progress. J Hypertens 2006 Dec; 24(12): 2341–3PubMedCrossRefGoogle Scholar
  42. 42.
    Babamoto KS, Hirokawa WT. Doxazosin: a new alpha 1-adrenergic antagonist. Clin Pharm 1992 May; 11(5): 415–27PubMedGoogle Scholar
  43. 43.
    Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002 Jun; 16(3): 359–69PubMedCrossRefGoogle Scholar
  44. 44.
    Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg 2002 Aug; 26(8): 1037–42PubMedCrossRefGoogle Scholar
  45. 45.
    Janetschek G, Finkenstedt G, Gasser R, et al. Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol 1998 Aug; 160(2): 330–4PubMedCrossRefGoogle Scholar
  46. 46.
    Möbius E, Nies C, Rothmund M. Surgical treatment of pheochromocytomas: laparoscopic or conventional? Surg Endosc 1999 Jan; 13(1): 35–9PubMedCrossRefGoogle Scholar
  47. 47.
    Joris JL, Chiche JD, Canivet JL, et al. Hemodynamic changes induced by laparoscopy and their endocrine correlates: effects of clonidine. J Am Coll Cardiol 1998 Nov; 32(5): 1389–96PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Dario Cotesta
    • 1
  • Luigi Petramala
    • 1
  • Valentina Serra
    • 1
  • Mario Pergolini
    • 1
  • Eleonora Crescenzi
    • 1
  • Laura Zinnamosca
    • 1
  • Giorgio De Toma
    • 2
  • Antonio Ciardi
    • 2
  • Iacopo Carbone
    • 3
  • Rita Massa
    • 3
  • Sebastiano Filetti
    • 3
  • Claudio Letizia
    • 1
  1. 1.Department of Clinical SciencesUniversity “Sapienza”RomeItaly
  2. 2.Department of Surgery “Pietro Valdoni”University “Sapienza”RomeItaly
  3. 3.Department of RadiologyUniversity “Sapienza”RomeItaly

Personalised recommendations